Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
Date:10/27/2009

NEW YORK, Oct. 27 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC). The study evaluated the effects of adding one of three doses of INT-747 or placebo to ursodeoxycholic acid (UDCA) therapy in patients who did not respond adequately to UDCA therapy alone. All three doses of INT-747 added to UDCA produced a statistically highly significant reduction in alkaline phosphatase (Alk Phos) levels, the primary endpoint at the end of the 12-week treatment period, as compared to patients receiving placebo and UDCA. Alk Phos is a liver enzyme routinely used to evaluate the clinical status and disease progression of PBC patients. All the INT-747 doses added to UDCA produced 20% or greater reductions in Alk Phos, with similar significant falls in other clinical liver enzymes. With the exception of a higher incidence of pruritus (itching) in the two top INT-747 dose groups, adverse events were generally similar across all groups.

PBC is a chronic autoimmune disease of the liver marked by the slow progressive destruction of the small bile ducts within the liver, which may lead to liver failure and the need for( )liver transplantation. PBC primarily afflicts women with up to 300,000 patients estimated worldwide.

Keith Lindor, MD, Dean of the Medical School at Mayo Clinic and a key investigator in the study, commented, "UDCA is the only drug currently approved for PBC and it does not adequately treat the disease in many patients. There is a real need for novel therapies and the clinically meaningful results from this study are supportive of INT-747's potential as an effective drug for PBC."

Mark Pruzanski, MD, Intercept's President and Chief Executive Officer, added, "The remarkable performance of INT-747 in this study, together with the previously announced positive
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
2. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
3. BioMarin Acquires Huxley Pharmaceuticals, Inc.
4. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
5. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
7. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
8. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
9. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
(Date:1/23/2015)... South Africa , Jan. 23, 2015   Leatt ... of personal protective equipment for all forms of sports, ... flagship Leatt-Brace® neck brace, announced today that the UISP ... federation, now requires all riders to wear a neck ...
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... NEW YORK, Sept. 28, 2011 Visionsense Corp announces ... was used in its 500th neurosurgical procedure with the ... (Al Lerner Chair and Vice-Chairman, Dept of Neurosurgery at ... performed a transsphenoidal resection of a pituitary adenoma in ...
... 2011 Low rates of meningococcal vaccination among adolescents ... Human Services Agency (HHSA) to join forces with the ... San Diego Meningitis Awareness Week. A national public health ... third of adolescents in California have not been vaccinated ...
Cached Medicine Technology:Local School Nurses Unite Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens in San Diego 2Local School Nurses Unite Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens in San Diego 3Local School Nurses Unite Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens in San Diego 4Local School Nurses Unite Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens in San Diego 5
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
(Date:1/22/2015)... a new blog post presenting a list of vehicles that cannot ... Some types of vehicles cannot be covered under an ordinary auto ... see if their vehicle qualifies for auto insurance coverage. , ... that cannot be covered by a plan. Clients have little options ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... That can lead to under-reporting when applying for driver,s ... -- In patients with focal epilepsy, simply asking how ... of their seizure frequency, German research suggests. , Reminding ... not help, either, because they may be unaware of ...
... 15 Dr. Douglas Kalman of Miami Research,Associates delivered ... the,endurance athlete at the International Society of Sports Nutrition ... Kalman presented "Whey, Casein, Soy: Why Protein Sources are ... studies that examined just how, and if, these varied ...
... Mass., Nov. 15 Andy Ambrose has joined ... David Test, division sales manager. Ambrose is based ... relationships in,the south Texas region. He joins ... served as,regional vice president for the company,s retirement ...
... which don,t , THURSDAY, Nov. 15 (HealthDay News) -- Experts ... cystic fibrosis (CF). , The guidelines were based on a ... older. , "Physicians treating patients with CF are faced with ... clinicians will find these recommendations to be useful in their ...
... November 15, 2007 A recently published special ... the contributions from experts in the field of ... Fourth Annual Meeting on Brain aging and Dementia: ... Perugia in October 2006 under the auspices of ...
... to change diet, get more exercise, study found , THURSDAY, ... blood pressure are less likely than younger patients to receive ... their blood pressure, a new study finds. , A team ... data from a U.S. Centers for Disease Control and Prevention ...
Cached Medicine News:Health News:Some Epilepsy Patients Not Always Aware of Seizures 2Health News:Presentation at ISSN Highlights Soy Protein Advantages for Endurance Athletes 2Health News:Experts Release New Cystic Fibrosis Guidelines 2Health News:Journal of Alzheimer's Disease special issue explores multifaceted aspects of AD 2Health News:Journal of Alzheimer's Disease special issue explores multifaceted aspects of AD 3Health News:Older Hypertension Patients Less Likely to Get Lifestyle Advice 2
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
... Dehydroepiandrosterone (5-Androstene-3-0L-17-one,Androstenolone, Dehydroisoandrosterone,Transdehydroandrosterone, DHEA) is ... blood mostly in its,sulfate form ... is based on the competition ... An,unknown amount of DHEA-S present ...
Beta-2 Microglobulin EIA Lipid / Protein Quantification 025-BC-1061...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Medicine Products: